Participation by people of all backgrounds is critical to developing vaccines that protect against infectious diseases like RSV and Shingles. The greater the diversity among clinical trial participants, the more we can learn about potential vaccines and how they work for different people, including those most at-risk because of their age, race, ethnicity, or where and how they live. Each new vaccine breakthrough helps us reach more people to prevent and reduce the spread of disease.
Help make receiving two important vaccines at the same time easier and more convenient.
RSV is a contagious respiratory virus and shingles is a painful, blistering rash caused by reactivation of the same virus that causes chickenpox. Both RSV and Shingles can lead to hospitalization and other complications, especially in older adults and those with weakened immune systems.
The PISSARRO clinical trial will help us understand how people respond to receiving an RSV vaccine (ABRYSVO®) given at the same time as a vaccine to prevent shingles (SHINGRIX), compared to when they are given separately, at different times.
Who may participate
Joining a clinical trial is an important and personal decision. We thank you for considering participating.
This clinical trial is enrolling adults who:
- Are 50 years of age or older
- Are generally healthy or have stable chronic medical conditions
- Have not previously received any RSV vaccine (ABRYSVO®, AREXVY, mRESVIA®)
- Have not previously received a non-live shingles vaccine (SHINGRIX)
- Have not been diagnosed with shingles in the past 12 months
- Do not have a history of severe allergic reactions associated with any vaccine
There are other requirements for taking part in this clinical trial. The study team will explain these to you if you’d like to learn more.
To see if you may qualify to participate, click “Get Started.”
Medical and vaccination history
Generally healthy, and have not previously received any RSV vaccine or a non-live shingles vaccine
Age
50 years of age or older
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study is a good fit for you and you choose to take part, you will receive an RSV vaccine (ABRYSVO®) and two doses of shingles vaccine (SHINGRIX).
You will randomly be assigned to one of two group study vaccine groups:
- Group 1: Participants will receive their 1st dose of the shingles vaccine and the RSV vaccine at their first study visit. The 2nd dose of the shingles will be given 2 months later.
- Group 2: Participants will receive the 1st dose of the shingles vaccine at their first study visit and the RSV vaccine at their second study visit. The 2nd dose of the shingles vaccine will be given 2 months after the 1st dose.
Both study vaccines have been approved for use in the United States.
Length of study treatment
4 months
Number of study visits
4 in person study visits and 1 by phone or video
About the study vaccines
The vaccines used in this study are an RSV vaccine (ABRYSVO®) and a shingles vaccine (SHINGRIX). Both study vaccines have been approved for use in the United States.
The RSV vaccine (ABRYSVO®) is given as a single injection, while the shingles vaccine (SHINGRIX) is given in a 2 dose series of injections at least 2 months apart.
Your participation matters
Your participation matters
Frequently asked questions
Will I know which study group I’m assigned to?
Yes, you and the study team will know which group you’ve been assigned to, including which vaccine you will receive. However, no one including you, the study doctor, or the study team can choose which group you will be in.
What are the possible side effects?
As with any vaccine, local reactions at the injection site such as redness, swelling, or pain is common. There is also potential for other symptoms like a mild fever or fatigue (tiredness). All known side effects will be explained in the Informed Consent Document (ICD), and the study doctor will discuss these with you before you join the clinical trial. If we learn any new information about the study vaccines during the clinical trial, the study doctor will share that with you as well.
What kinds of tests and procedures are you going to perform?
At the beginning of the clinical trial, the study doctor will ask you about your medical history, including previous vaccinations and any medications you are currently taking. You will be given an electronic diary (eDiary) to complete daily for one week after your vaccines so the study team can monitor your health. You will also have your blood drawn up to four times. The study team will provide more information about study tests and procedures before you choose to join the clinical trial.
Is there a cost to participate?
The study vaccines and study-related procedures will be provided at no cost. You will also be compensated for each study visit completed.
What if I change my mind?
Participating in a clinical trial is completely voluntary (your choice). You can choose to leave the study at any time, for any reason, without penalty to you. If you decide not to participate, your future medical care will not be affected.
